// App-Quantinova.ai

268 : Ivig, but Not a Monoclonal Anti-RBC Antibody, Requires the Presence of Gr-1+ Cells to Ameliorate Immune Thrombocytopenia in a Murine Model

Researchers

Presenter

  • Alan H Lazarus

Principal Investigators

  • N/A

Medical Centers

  • Canadian Blood Services, Toronto, ON, Canada

  • Research and Development, Canadian Blood Services, Vancouver, BC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Immune thrombocytopenia

  • Neutropenia

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • IVIG

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved